taliglucerase alfa (Rx)

Brand and Other Names:Elelyso
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection, lyophilized powder for reconstitution

  • 200units/vial

Gaucher Disease

Indicated for treatment of Type 1 Gaucher disease in patients aged ≥4 years with a confirmed diagnosis

Treatment-naïve

  • 60 units/kg IV every other week

Switching from imiglucerase

  • Currently on stable imiglucerase dose: Begin taliglucerase alfa at same units/kg dosage of imiglucerase when switching from imiglucerase to taliglucerase alfa
  • Administer for long-term treatment as IV infusion every other week
  • Adjust dosage based on achievement and maintenance each patient’s therapeutic goals

Dosage Forms & Strengths

injection, lyophilized powder for reconstitution

  • 200units/vial

Gaucher Disease

Indicated for enzyme replacement in patients with confirmed diagnosis of type 1 (non-neuropathic) Gaucher disease

<4 years: Safety and efficacy not established

≥4 years: 60 units/kg IV every other week

Switching from imiglucerase

  • Currently on stable imiglucerase dose: Begin taliglucerase alfa at same units/kg dosage of imiglucerase when switching from imiglucerase to taliglucerase alfa
  • Administer for long-term treatment as IV infusion every other week
  • Adjust dosage based on achievement and maintenance each patient’s therapeutic goals
Next:

Adverse Effects

>10%

Treatment-naïve adults

  • Headache (19%)
  • Arthralgia (13%)

Treatment naïve children and adolescents

  • Vomiting (≥10%)

Switch from imiglucerase adults and children

  • Arthralgia (13%)
  • Headache (13%)

1-10%

Treatment-naïve adults

  • Fatigue (9%)
  • Nausea (9%)
  • Dizziness (9%)
  • Abdominal pain (6%)
  • Pruritus (6%)
  • Flushing (6%)
  • Vomiting (6%)
  • Urticaria (6%)

Switch from imiglucerase adults and children

  • Pain in extremity (10%)

Postmarketing Reports

Gastrointestinal disorders: Vomiting, diarrhea

General disorders and administration site conditions: Fatigue

Immune system disorders: Anaphylaxis, Type III immune-mediated fixed drug eruption

Musculoskeletal and connective tissue disorders: Back pain

Previous
Next:

Warnings

Contraindications

None

Cautions

Anaphylaxis reported; if anaphylaxis occurs, discontinue infusion immediately and initiate appropriate treatment

Allergic and infusion reactions are common and include headache, chest pain or discomfort, asthenia, fatigue, urticaria, erythema, increased blood pressure, back pain, arthralgia, and flushing; if allergic or infusion reactions occur, decrease the infusion rate or temporarily stop the infusion; antihistamines and/or antipyretics may be administered; medical support should be readily available when taliglucerase alfa administered; observe patients closely for an appropriate period of time after administration; reactions have occurred up to 3 hr after the start of infusion

Consider risks and benefits of re-administering taliglucerase alfa in patients who have experienced severe reaction associated with taliglucerase alfa; use caution upon rechallenge; appropriate medical support should be readily available

As with all therapeutic proteins, development of IgG anti-drug antibodies (ADA) has been reported (53%); unknown if presence of ADA is associated with higher risk of infusion reactions or immunogenicity

Monitor patients that have had an immune response to other enzyme replacement therapies or who are switching to taliglucerase alfa; unknown if these patients are at higher risk of infusion reactions

Dizziness and fatigue reported; caution patients against performing dangerous tasks that require mental alertness, including driving heavy machinery

Previous
Next:

Pregnancy & Lactation

Pregnancy

Insufficient data available on use in pregnant females to inform a drug-associated risk

Animal data

  • When pregnant rats and rabbits were administered IV taliglucerase alfa at doses up to 5 times the recommended human dose, there was no evidence of embryofetal toxicity

Clinical considerations

  • Women with Type 1 Gaucher disease have an increased risk of spontaneous abortion if disease symptoms are not treated and controlled preconception and during pregnancy
  • Pregnancy may exacerbate existing Type 1 Gaucher disease symptoms or result in new disease manifestations
  • Type 1 Gaucher disease manifestations may lead to adverse pregnancy outcomes, including hepatosplenomegaly which can interfere with the normal growth of a fetus and thrombocytopenia which can lead to increased bleeding and possible postpartum hemorrhage requiring transfusion

Lactation

There are no data on taliglucerase alfa in human milk, effects on breast fed infants, or effects on milk production

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Gaucher disease is caused by a deficiency of the enzyme to catalyze glucocerebrosidase resulting in lipid accumulation in the spleen, liver, kidneys, and other organs; major signs include liver or spleen damage, anemia, and thrombocytopenia

Taliglucerase alfa catalyzes the hydrolysis of glucocerebroside to glucose and ceramide which results in reduced spleen and liver enlargement, and increased RBCs and platelets

Absorption

AUC

  • Children and adolescents (30 units/kg): 1416 ng⋅hr/mL
  • Children and adolescents (60 units/kg): 2984 ng⋅hr/mL
  • Adults (30 units/kg): 2007 ng⋅hr/mL
  • Adults (60 units/kg): 6459 ng⋅hr/mL

Distribution

Vd (steady-state)

  • Children and adolescents (30 units/kg): 14.9 L
  • Children and adolescents (60 units/kg): 8.8 L
  • Adults (30 units/kg): 11.7 L
  • Adults (60 units/kg): 10.7 L

Elimination

Clearance

  • Children and adolescents (30 units/kg): 30.5 L/hr
  • Children and adolescents (60 units/kg): 15.8 L/hr
  • Adults (30 units/kg): 30.5 L/hr
  • Adults (60 units/kg): 18.5 L/hr

Half-life

  • Children and adolescents (30 units/kg): 37.1 min
  • Children and adolescents (60 units/kg): 32.5 min
  • Adults (30 units/kg): 18.9 min
  • Adults (60 units/kg): 28.7 min
Previous
Next:

Administration

IV Preparation

Remove required number of vials from refrigerator; do not leave vials at room temperature >24 hr before reconstitution; do not heat or microwave vials

Reconstitute each vial with 5.1 mL of Sterile Water for Injection to yield concentration of 40 units/mL

Upon reconstitution, mix vials gently; DO NOT SHAKE

Before further dilution, visually inspect vials; solution should be clear and colorless; discard if solution is discolored or if foreign particulate matter is present

Withdraw calculated dose from reconstituted vials and dilute with 0.9% NaCl, to a final volume of 100-120 mL (in children and adolescents) and 130-150 mL (in adults) should be used

For adults, if volume of reconstituted product alone ≥130 to 150 mL, then final volume should not exceed 200 mL

Mix gently; DO NOT SHAKE

Since this is a protein solution, slight flocculation (described as translucent fibers) occurs occasionally after dilution

IV Administration

Infuse diluted solution IV and filtered through in-line, low protein-binding 0.2 micron filter

Adults: Initial IV infusion rate of 1.2 mL/min; may increase up to 2.2 mL/min after tolerability established

Children and adolescents: Initial IV infusion rate of 1 mL/min; may increase up to 2 mL/min after tolerability established

Infuse total solution volume over at least 1 hr

Storage

Unused vials

  • Refrigerate at 2-8ºC (36-46ºF); protect from light

Reconstituted vials

  • Contains no preservative
  • Use immediately once reconstituted
  • If immediate use not possible, refrigerate at 2-8ºC (36-46ºF) for up to 24 hr; protect from light OR
  • Store at room temperature (20-25ºC [68-77ºF]) for up to 4 hr without protection from light

Diluted solution

  • Refrigerate at 2-8ºC (36-46ºF) for up to 24 hr; protect from light
  • Do not freeze; discard any unused product
Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.